The purpose of this study is to develop a prospective cohort of patients with and without cardiac sarcoidosis as well as active and inactive disease to develop a prospective biobank from which exosome analysis of peripheral blood will derive unique biomarkers of disease activity in cardiac sarcoidosis.
Adults ≥18 years.
Patients referred to the Cardiac Sarcoid Clinic with a clinical suspicion or a previously confirmed diagnosis of cardiac sarcoidosis.
Undergoing FDG-PET as part of standard care.
Ability to provide informed consent.
None
Patients referred to the Cardiac Sarcoid Clinic with a clinical suspicion or a previously confirmed diagnosis of cardiac sarcoidosis.
Cohort
Prospective
Exosome Analysis
Other interventionBlood Samples will undergo exosome profiling using mass spectrometry and/or other discovery-based approaches
Number of successful biomarker validations
Biomarker validation will be defined as ability to discriminate active from inactive or quiescent disease as assessed by FDG-PET
Click on the lead sponsor to view all of their trials.
